이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Atara Biotherapeutics 관리

관리 기준 확인 3/4

Atara Biotherapeutics' CEO는 Pascal Touchon, Jun2019 에 임명되었습니다 의 임기는 5.08 년입니다. 총 연간 보상은 $ 4.38M, 16.5% 로 구성됩니다. 16.5% 급여 및 83.5% 보너스(회사 주식 및 옵션 포함). 는 $ 196.77K 가치에 해당하는 회사 주식의 0.48% 직접 소유합니다. 196.77K. 경영진과 이사회의 평균 재임 기간은 각각 3.5 년과 6.9 년입니다.

주요 정보

Pascal Touchon

최고 경영자

US$4.4m

총 보상

CEO 급여 비율	16.5%
CEO 임기	5.1yrs
CEO 소유권	0.5%
경영진 평균 재임 기간	3.5yrs
이사회 평균 재임 기간	6.9yrs

최근 관리 업데이트

Recent updates

New Forecasts: Here's What Analysts Think The Future Holds For Atara Biotherapeutics, Inc. (NASDAQ:ATRA)

May 14

Revenues Working Against Atara Biotherapeutics, Inc.'s (NASDAQ:ATRA) Share Price Following 26% Dive

May 11

Atara Biotherapeutics: Opportunity As They Sell Off Their Approved Asset For Longer Runway

Feb 06

Here's Why Atara Biotherapeutics (NASDAQ:ATRA) Must Use Its Cash Wisely

Oct 17

Earnings Working Against Atara Biotherapeutics, Inc.'s (NASDAQ:ATRA) Share Price Following 32% Dive

May 18

Need To Know: Analysts Are Much More Bullish On Atara Biotherapeutics, Inc. (NASDAQ:ATRA)

Feb 13

Analysts Have Just Cut Their Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Revenue Estimates By 16%

Nov 22

EMA panel backs approval of Atara's Ebvallo for transplant complication

Oct 14

Atara Bio to get additional $30M milestone payment under collaboration with Pierre Fabre

Sep 28

Atara: 2 Possible Regulatory Approvals For Tab-Cel, Plus CAR T Pipeline

Aug 17

Atara adds 16% ahead of Phase 2 data for multiple sclerosis candidate

Jul 12

Atara Biotherapeutics, Inc.'s (NASDAQ:ATRA) Intrinsic Value Is Potentially 42% Above Its Share Price

Jul 03

Time To Worry? Analysts Just Downgraded Their Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Outlook

May 11

CEO 보상 분석

Pascal Touchon 의 보수는 Atara Biotherapeutics 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Mar 31 2024	n/a	n/a	-US$233m
Dec 31 2023	US$4m	US$723k	-US$276m
Sep 30 2023	n/a	n/a	-US$286m
Jun 30 2023	n/a	n/a	-US$305m
Mar 31 2023	n/a	n/a	-US$215m
Dec 31 2022	US$5m	US$718k	-US$228m
Sep 30 2022	n/a	n/a	-US$247m
Jun 30 2022	n/a	n/a	-US$248m
Mar 31 2022	n/a	n/a	-US$350m
Dec 31 2021	US$5m	US$681k	-US$340m
Sep 30 2021	n/a	n/a	-US$328m
Jun 30 2021	n/a	n/a	-US$318m
Mar 31 2021	n/a	n/a	-US$311m
Dec 31 2020	US$5m	US$655k	-US$307m
Sep 30 2020	n/a	n/a	-US$304m
Jun 30 2020	n/a	n/a	-US$301m
Mar 31 2020	n/a	n/a	-US$298m
Dec 31 2019	US$7m	US$319k	-US$291m

보상 대 시장: Pascal 의 총 보상 ($USD 4.38M )은 US 시장( $USD 683.56K ).

보상과 수익: Pascal 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.

CEO

Pascal Touchon (61 yo)

5.1yrs

테뉴어

US$4,375,125

보상

Dr. Pascal Touchon, D.V.M., serves as Independent Director at Ipsen S.A. since October 4, 2023. He has been President, Chief Executive Officer and Director at Atara Biotherapeutics, Inc. since June 24, 201...

리더십 팀

이름	위치	테뉴어	보상	소유권
Pascal Touchon	President	5.1yrs	US$4.38m	0.48% $ 196.8k
Anhco Nguyen	Executive VP and Chief Scientific & Technical Officer	3.2yrs	US$2.28m	0.19% $ 79.0k
K. Murugan	Executive VP & Chief Legal Officer	4.3yrs	US$2.31m	0.18% $ 74.0k
Eric Hyllengren	Executive VP & Chief Financial Officer	1.3yrs	데이터 없음	0.15% $ 61.3k
Alex Chapman	Vice President of Corporate Communications & Investor Relations	no data	데이터 없음	데이터 없음
Jill Henrich	Executive VP and Global Head of Regulatory Affairs & Quality	3.8yrs	데이터 없음	0.12% $ 49.9k
Dan Maziasz	Executive VP & Chief Business Officer	3.5yrs	데이터 없음	데이터 없음
Rajani Dinavahi	Senior VP & Chief Medical Officer	less than a year	데이터 없음	데이터 없음

3.5yrs

평균 재임 기간

51yo

평균 연령

경험이 풍부한 관리: ATRA 의 관리팀은 경험 ( 3.4 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Pascal Touchon	President	5.1yrs	US$4.38m	0.48% $ 196.8k
William Heiden	Independent Director	8.7yrs	US$237.23k	0.13% $ 51.7k
Matthew Fust	Independent Director	10.3yrs	US$239.73k	0.043% $ 17.7k
Carol Gallagher	Chairman & Lead Independent Director	11.5yrs	US$260.23k	0.35% $ 143.7k
Ameet Mallik	Independent Director	2.9yrs	US$219.52k	0.017% $ 7.0k
Maria Roncarolo	Independent Director	4.2yrs	US$229.73k	0.026% $ 10.7k

6.9yrs

평균 재임 기간

60yo

평균 연령

경험이 풍부한 이사회: ATRA 의 이사회는 경험(평균 재직 기간 6.8 년)으로 간주됩니다.

Atara Biotherapeutics 관리

관리 기준 확인 3/4

주요 정보

최근 관리 업데이트

President notifies of intention to sell stock

Atara Biotherapeutics, Inc., Annual General Meeting, Jun 10, 2024

Atara Biotherapeutics, Inc. Announces Termination of Manher (Aj) Joshi as Executive Vice President, Chief Medical Officer, Effective as of February 2, 2024

Independent Director recently bought US$101k worth of stock

Atara Biotherapeutics, Inc. Announces Resignation of Beth Seidenberg from the Board of Directors

Insufficient new directors

Recent updates

New major risk - Financial position

Atara Biotherapeutics Submits Tabelecleucel (Tab-cel) Biologics License Application for Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease with U.S. FDA

President notifies of intention to sell stock

Consensus revenue estimates increase by 17%

New Forecasts: Here's What Analysts Think The Future Holds For Atara Biotherapeutics, Inc. (NASDAQ:ATRA)

Revenues Working Against Atara Biotherapeutics, Inc.'s (NASDAQ:ATRA) Share Price Following 26% Dive

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Atara Biotherapeutics, Inc., Annual General Meeting, Jun 10, 2024

Consensus revenue estimates increase by 117%

Price target decreased by 13% to US$4.20

Full year 2023 earnings: EPS in line with expectations, revenues disappoint

Atara Biotherapeutics, Inc. Announces Submission of Investigational New Drug Application for ATA3219 for Treatment of Lupus Nephritis

Atara Biotherapeutics: Opportunity As They Sell Off Their Approved Asset For Longer Runway

Atara Biotherapeutics, Inc. and Pierre Fabre Laboratories Announce Publication of Phase 3 ALLELE Tab-cel®? Data in The Lancet Oncology

Consensus revenue estimates increase by 50%

Atara Biotherapeutics, Inc. has announced a Derivatives Offering in the amount of $15 million.

Atara Biotherapeutics, Inc. Announces Termination of Manher (Aj) Joshi as Executive Vice President, Chief Medical Officer, Effective as of February 2, 2024

Atara Biotherapeutics, Inc. Presents Positive Preclinical Data on ATA3431, A Next-Generation Allogeneic CD20/CD19-Targeted CAR, at the 65th ASH Annual Meeting

Price target increased by 17% to US$4.83

Consensus revenue estimates increase by 33%

Independent Director recently bought US$101k worth of stock

Consensus revenue estimates decrease by 27%

Price target decreased by 57% to US$6.40

Atara Biotherapeutics, Inc. Announces Primary Analysis Data from Phase 2 EMBOLD Clinical Trial of ATA188 in Non-Active Progressive Multiple Sclerosis

Atara Biotherapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $100 million.

Atara Biotherapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $100 million.

Third quarter 2023 earnings released

New major risk - Revenue and earnings growth

Here's Why Atara Biotherapeutics (NASDAQ:ATRA) Must Use Its Cash Wisely

Atara Biotherapeutics, Inc. Announces Plans to Submit Tab-cel® BLA in Second Quarter 2024 Following FDA Agreement on Comparability

New major risk - Share price stability

Price target decreased by 8.1% to US$14.82

Consensus revenue estimates decrease by 23%, EPS upgraded

New major risk - Revenue and earnings growth

Price target increased by 15% to US$18.48

Atara Biotherapeutics, Inc. to Report Q2, 2023 Results on Aug 08, 2023

New major risk - Financial position

Consensus revenue estimates fall by 21%

Atara Biotherapeutics, Inc. Announces Resignation of Beth Seidenberg from the Board of Directors

Insufficient new directors

Price target decreased by 13% to US$16.13

President recently sold US$61k worth of stock

Earnings Working Against Atara Biotherapeutics, Inc.'s (NASDAQ:ATRA) Share Price Following 32% Dive

Consensus revenue estimates fall by 55%

Consensus revenue estimates fall by 61%

Price target decreased by 20% to US$14.74

Price target decreased by 13% to US$16.43

Atara Biotherapeutics, Inc. Announces Executive Changes

Consensus revenue estimates decrease by 11%, EPS upgraded

Need To Know: Analysts Are Much More Bullish On Atara Biotherapeutics, Inc. (NASDAQ:ATRA)

Full year 2022 earnings: EPS and revenues miss analyst expectations

Pierre Fabre and Atara Biotherapeutics Announce the Transfer of the European Commission Marketing Authorization for EBVALLO(TM)

Atara Biotherapeutics, Inc. to Report Q4, 2022 Results on Feb 08, 2023

Atara Biotherapeutics Announces Changes to Its Board of Directors

Atara Biotherapeutics, Inc. Appoints Carol Gallagher as Chair of the Board of Directors

Atara Biotherapeutics Presents Updated Clinical Data from Pivotal Phase 3 Trial (Allele) of Tab-Cel(R) At the 64Th American Society of Hematology (Ash) Annual Meeting

Analysts Have Just Cut Their Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Revenue Estimates By 16%

Price target increased to US$23.67

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Atara Biotherapeutics, Inc. to Report Q3, 2022 Results on Nov 08, 2022

Atara Biotherapeutics, Inc. Presents New MRI and Updated Open-Label Extension Data from Phase 1 Study of ATA188 in Progressive Multiple Sclerosis at ECTRIMS 2022

CHMP Recommends Approval of Atara Biotherapeutics, Inc. Ebvallo (Tabelecleucel) for the Treatment of Epstein-Barr Virus-Positive Post-Transplant Lymphoproliferative Disease

EMA panel backs approval of Atara's Ebvallo for transplant complication

Atara Bio to get additional $30M milestone payment under collaboration with Pierre Fabre

Atara: 2 Possible Regulatory Approvals For Tab-Cel, Plus CAR T Pipeline

Atara Biotherapeutics, Inc. to Terminate Kristin Yarema as Senior Vice President and Chief Commercial Officer, Effective as of November 15, 2022

Price target increased to US$25.83

Atara Biotherapeutics, Inc. to Report Q2, 2022 Results on Aug 08, 2022

Consensus forecasts updated